5-MeO-DBT

5-MeO-DBT (5-Methoxy-N,N-dibutyltryptamine, 5-MeO-BET) is a rare substituted tryptamine derivative, which is thought to be a psychoactive substance and was identified in a designer drug sample by a forensic laboratory in Slovenia in March 2021,^[1] although only analytical studies have been conducted and no pharmacological data is available.^[2][3][4] It is nevertheless controlled under drug analogue legislation in a number of jurisdictions.

5-MeO-DBT

Clinical data
Other names	5-methoxy DBT; N,N-Dibutyl-5-methoxy-1H-indole-3-ethanamine
Identifiers
IUPAC name N-Butyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]butan-1-amine
CAS Number	73785-42-9
PubChem CID	53485365
ChemSpider	30798625
UNII	Q454YC4LIK
CompTox Dashboard (EPA)	DTXSID10704547
Chemical and physical data
Formula	C19H30N2O
Molar mass	302.462 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCN(CCCC)CCC1=CNC2=C1C=C(C=C2)OC
InChI InChI=1S/C19H30N2O/c1-4-6-11-21(12-7-5-2)13-10-16-15-20-19-9-8-17(22-3)14-18(16)19/h8-9,14-15,20H,4-7,10-13H2,1-3H3 Key:WVGCRISHWANOTO-UHFFFAOYSA-N

Legal status

5-MeO-DBT was made schedule I at the state level in Alabama on September 13th, 2024.^[5]

See also

• Dibutyltryptamine
• 4-HO-DBT
• 4-HO-DSBT
• 5-MeO-DET
• 5-MeO-EPT
• 5-MeO-DPT